CompanyALLRNasdaqBoston, MA

Allarity Therapeutics

Allarity Therapeutics develops stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer in clinical stage.

SEC EDGAR ClinicalTrials.gov allarity.com

8-KOct 1Latest SEC filing

Sep 1Latest story

August 2026

Allarity completes stenoparib manufacturing campaign, gets key US patent and CLIA certification

Aug 14Quarterly updateAllarity Therapeutics